Company Overview and News

1
Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?

14h zacks
Medtronic plc’s (MDT - Free Report) Restorative TherapiesGroup (“RTG”) has been on a strong growth trajectory of late, courtesy of solid contribution from majority of the sub-segments.
INGN AMED ISRG MZOR MDT

1
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?

15h zacks
Medtronic plc’s (MDT - Free Report) Diabetes Group has been on a solid growth trajectory of late, courtesy of encouraging contributions from majority of the sub-segments.
INGN AMED ISRG MDT

6
Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure

2018-08-17 zacks
Intuitive Surgical, Inc (ISRG - Free Report) is currently a top performer in the MedTech space. Improved price performance, better-than-expected earnings results, significant exposure to Artificial Intelligence (AI) trends in healthcare and strong fundamentals instill investors’ optimism in the stock.
COO HD INGN PSTG HEAR ISRG OXY

8
Hologic Launches Fluent Fluid Management System, Widens Suite

2018-08-17 zacks
Hologic, Inc. (HOLX - Free Report) recently announced the launch of new Fluent fluid management system in the United States. Per the company, this system is embedded with features that simplify and improvise the fluid management for hysteroscopic procedures.
HD INGN PSTG HEAR AMED ISRG OXY HOLX

0
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology

2018-08-16 zacks
AngioDynamics (ANGO - Free Report) recently announced the acquisition of BioSentry Tract Sealant System (BioSentry) technology from Surgical Specialties, LLC. Notably, the system will be integrated into the company’s core Oncology business. A 12-person commercial organization of Surgical Specialties will join AngioDynamics to expand the reach of its Oncology business.
MASI ANGO INGN ISRG

0
Wright Medical Strong Overseas, Back Order Issues Persist

2018-08-16 zacks
On Aug 14, we issued an updated research report on Wright Medical Group N.V. (WMGI - Free Report) . The company’s international expansion is promising, while back order issues prevail.
MASI INGN ISRG

3
Here's Why You Should Invest in Align Technology (ALGN) Now

2018-08-16 zacks
Align Technology, Inc. (ALGN - Free Report) has been gaining investors’ confidence on consistently positive results. Over the past three months, the company’s share price has outperformed its industry. The stock has gained 21.7% compared with the industry’s 5.1%. The company has outperformed the 4.7% gain of the S&P 500 market as well.
ALGN INGN AMED ISRG

1
Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm

2018-08-16 zacks
Medtronic plc (MDT - Free Report) reached a new milestone with respect to its Aortic & Peripheral Vascular (APV) business. The company recently announced the commercial launch of IN.PACT Admiral Drug-Coated Balloon (DCB) in Japan.
INGN AMED ISRG MDT

114
18 High-Growth Stocks With Massive Upside Ahead

2018-08-15 investorplace - 6
This has been a market that favors high-growth stocks and not value plays. Obviously, the rising tide of the nine-year-plus bull market has lifted value boats as well. But clearly, the market of late has prioritized revenue growth over profit growth, to the point that many longtime value investors are in something close to despair.
JD GOOS FB DWCH FIT BZUN CUTR WDAY IRBT NFLX FIZZ WMT ADBE AMZN AGN LULU KO HOLX VFC SQ SHOP KDP DATA ISRG LOGI AYX MDT GPRO BABA ZLTQ PEP GOOGL VEEV ROKU ARLO MSFT ABMD NTGR

0
Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children

2018-08-15 zacks
Masimo Corporation (MASI - Free Report) recently announced that its SET Measure-through Motion and Low Perfusion pulse oximetry might be a useful initial screening method to identify children with Down Syndrome (DS) who are at a high risk of obstructive sleep apnea (OSA).
MASI RMD INGN RSMDF RMD ISRG

5
Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes

2018-08-14 zacks
On Aug 13, we issued an updated research report on Bio-Rad Laboratories, Inc. (BIO - Free Report) . We are upbeat about the company gaining from solid prospects in the blood typing market, while declining gross margin is a concern. The stock carries a Zacks Rank #3 (Hold).
ALGN BIO.B BIO INGN ISRG

0
Inogen's Solid Europe Business Shapes Q2, Prospects Bright

2018-08-14 zacks
On Aug 13, we issued an updated research report on Inogen, Inc. (INGN - Free Report) . The company’s strong global foothold and an upbeat 2018 view are major positives.
COO INGN ISRG

66
Buy High Quality Stocks On Turkey-Induced Weakness - Cramer's Mad Money (8/13/18)

2018-08-14 seekingalpha - 1
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, August 13.
ABT BURL CNC TMUSP TMUS RL PNK BAX ISRG AL EXPE BKNG DBX AMZN ALLLZ CZR GOOGL KSS VZ UNH

0
Becton, Dickinson Global Foothold Strong, Recalls Rampant

2018-08-13 zacks
On Aug 10, we issued an updated research report on Becton, Dickinson and Company (BDX - Free Report) . The company’s solid global expansion is a major positive, while product recall issues and foreign exchange headwinds persist.
INGN ISRG MDT

44
15 Stocks in the FANG Stocks Junior-Varsity League | InvestorPlace

2018-08-10 investorplace - 3
In athletics, the varsity team comprises the big-time players who are in the spotlight today. The junior-varsity team, meanwhile, comprises the smaller-time players who aren’t in the spotlight today, but have tons of potential and could very well be varsity players in the future.
FB PANW NFLX ISRG GOOG NVDA ILMN MTCH AMZN AAPL WING FTNT

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 46120E602